Definitive Contract 75N92020C00007
Award Date
7/30/20
Potential Completion Date
7/29/21
Potential Value
$6.6M
Federal Agency
National Heart Lung and Blood Institute
Awardee
Ginkgo Bioworks, Inc.
Ultimate Awardee
Not listed
NAICS Category
621511 - Medical Laboratories
PSC Category
Q301 - Reference Laboratory Testing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Boston, MA 02210, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This $50,216,772.13 Firm Fixed Price Delivery Order contract was awarded to Ginkgo Bioworks, Inc., a biotechnology company based in Boston, Massachusetts. The contract is for test surge and data sharing services under a larger Indefinite Delivery/Indefinite Quantity (IDIQ) vehicle held with the Centers for Disease Control and Prevention (CDC). The IDIQ has a total ceiling value of $118 million and an ultimate completion date of September 5, 2029. Ginkgo Bioworks has previously provided...
The Centers for Disease Control and Prevention (CDC) awarded a $76,575,638.04 firm-fixed-price contract to Ginkgo Bioworks, Inc., a Boston-based biotechnology company, to conduct genomic testing and surveillance of SARS-CoV-2 at five major U.S. international airports. The contract, which runs through March 21, 2025, requires Ginkgo Bioworks to collect a minimum of 483,000 biological samples per year from international travelers and perform on-site reverse transcription polymerase chain...
The U.S. Centers for Disease Control and Prevention (CDC) awarded a $85,741,227.24 Firm Fixed Price Definitive Contract to Ginkgo Bioworks, Inc., a biotechnology company in Boston, Massachusetts, for a Traveler-Based Genomic Surveillance Program. The contract has an ultimate completion date of March 21, 2028 and was not set aside for a specific business category. This contract appears to build on Ginkgo Bioworks' previous work with the CDC on COVID-19 genomic testing and surveillance at major...
This federal contract award is for a delivery order under the "Test Surge and Data Sharing Multiple Award IDIQ" issued by the Centers for Disease Control and Prevention (CDC). The prime contractor is Ginkgo Bioworks, Inc., a biotechnology company based in Boston, Massachusetts. The contract has a ceiling value of $449,761.53 and a completion date of May 15, 2025. It is a time and materials contract type, with no set-aside designation. The contract leverages Ginkgo Bioworks' expertise...
The Broad Institute, Inc., doing business as the Broad Institute of MIT and Harvard, has been awarded a definitive contract valued at $25.7 million by the National Institutes of Health's National Heart, Lung and Blood Institute to scale the Broad Institute's reverse transcription polymerase chain reaction (RT-PCR) process to support testing of over 100,000 samples per day. This contract is part of the Rapid Acceleration of Diagnostics (RADx) Advanced Technology Platforms program, which aims to...
This is a $1,205,149.24 Firm Fixed Price contract awarded by the Centers for Disease Control and Prevention (CDC) to Ginkgo Bioworks, Inc., a biotechnology company based in Boston, Massachusetts. The contract, titled "TRAVELER-BASED GENOMIC SURVEILLANCE," is for the provision of biotechnology services to support the CDC's public health monitoring and emergency response initiatives. The contract has an ultimate completion date of September 19, 2024 and was awarded on August 26, 2024....
This federal contract award is for an Indefinite Delivery/Indefinite Quantity (IDIQ) contract with the Centers for Disease Control and Prevention (CDC) for "Test Surge and Data Sharing" services. The $118 million IDIQ was awarded to Ginkgo Bioworks, Inc., a biotechnology company based in Boston, Massachusetts, on September 27, 2024. The contract has an ultimate completion date of September 5, 2029. This IDIQ is not designated as a set-aside contract. The IDIQ contract leverages...
The National Institutes of Health's National Heart, Lung and Blood Institute awarded an $18.2 million firm fixed price definitive contract to Quanterix Corporation as part of the Rapid Acceleration of Diagnostics initiative. The RADx program aims to expedite the development, commercialization, and implementation of Covid-19 testing technologies to significantly increase domestic testing capacity. Quanterix will support this objective through the delivery of diagnostic solutions over a two-year...
This is a $3,999,210.00 cost-plus-fixed-fee definitive contract awarded by the Department of the Navy Information Warfare Systems Command to Ginkgo Bioworks, Inc., a biotechnology firm based in Boston, for the DNA Recording Intrinsic Cellular Biointelligence (DRINC BIO) project. The contract has a completion date of May 21, 2025 and was awarded on May 2, 2023 with no set-aside designation. Ginkgo Bioworks provides research, testing, and production services related to cellular engineering, DNA...
This is a $354,267.22 firm fixed price definitive contract awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to Grip Molecular Technologies Inc., a small disadvantaged business. The contract involves research and development of ultra-sensitive photonic integrated circuit detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Influenza A antigens using graphene biosensors. The goal is to support the...